Polyrizon Ltd. Ordinary Shares Cash Flow Conversion Efficiency
Polyrizon Ltd. Ordinary Shares cash flow conversion efficiency. Based on the latest financial reports, Polyrizon Ltd. Ordinary Shares (PLRZ) has a cash flow conversion efficiency ratio of -0.099x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.82 Million) by net assets ($18.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Polyrizon Ltd. Ordinary Shares (2020–2024)
Cash flow conversion efficiency of Polyrizon Ltd. Ordinary Shares from 2020 to 2024. This chart illustrates how Polyrizon Ltd. Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Polyrizon Ltd. Ordinary Shares stock price today for real-time trading data and today's change.
Polyrizon Ltd. Ordinary Shares Cash Flow Conversion Ratio Explained
Polyrizon Ltd. Ordinary Shares cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Polyrizon Ltd. Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Polyrizon Ltd. Ordinary Shares ranked by their cash flow conversion efficiency. Also see market cap of Polyrizon Ltd. Ordinary Shares for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Karya Bersama Anugerah Pt
JK:KBAG
|
0.009x |
|
Schroder Oriental Income Fund
LSE:SOI
|
0.126x |
|
Xintela AB
ST:XINT
|
0.242x |
|
Ambitions Enterprise Management Co. L.L.C Class A Ordinary Shares
NASDAQ:AHMA
|
0.032x |
|
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
|
0.075x |
|
Ubis (Asia) Public Company Limited
BK:UBIS
|
0.047x |
|
LabGenomics Co. Ltd
KQ:084650
|
-0.034x |
|
Nusantara Almazia
JK:NZIA
|
0.007x |
Annual Cash Flow Conversion Efficiency for Polyrizon Ltd. Ordinary Shares (2020–2024)
The table below shows the annual cash flow conversion efficiency of Polyrizon Ltd. Ordinary Shares from 2020 to 2024. Review PLRZ free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $5.29 Million | $-1.15 Million | -0.217x | -107.72% |
| 2023-12-31 | $-191.00K | $-537.00K | 2.812x | +61.94% |
| 2022-12-31 | $-652.00K | $-1.13 Million | 1.736x | -98.94% |
| 2021-12-31 | $-3.00K | $-492.00K | 164.000x | +3694.52% |
| 2020-12-31 | $16.00K | $-73.00K | -4.563x | -- |
About Polyrizon Ltd. Ordinary Shares
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nas… Read more